Drug Trial Radar · NCT04051268
Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)
Last checked: Nov 20, 2026Latest source record: Jan 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,071
Actual
Start
Mar 2, 2020
Primary completion
Nov 24, 2021
Study completion Dec 1, 2021
Sponsor
- Lead sponsor
- PT Bio FarmaIndustry
- Sponsor type
- Industry
- First posted
- Aug 9, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 months, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase III study, Randomized, observer blind, lot to lot consistency, non inferiority to PQed typhoid conjugate vaccine and Typhoid Vi polysaccharide vaccine.
Conditions
- Safety Issues
- Immunogenicity
Interventions
Vi-DT Typhoid Conjugate VaccineBiological
1 dose of Investigational Product
PQed Typhoid Conjugate VaccineBiological
1 dose of Active Comparator
Vi Polysaccharide VaccineBiological
1 dose of Active Comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- ImmunogenicityTime frame: 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jatinegara Primary Health Care
Jakarta, Jakart, Indonesia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.